-
Kura Oncology NASDAQ:KURA Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets; however, no molecular mechanism of action had been determined that could explain its clinical activity across a range of solid tumor and hematologic indications. Leveraging advances in next generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to Breakthrough Therapy Designation, tipifarnib has been granted Fast Track designation by the FDA for the treatment of patients with HRAS mutant HNSCC. In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in a number of additional genetically defined tumor types. Kura has received multiple issued patents for tipifarnib, providing patent exclusivity in the U.S. and foreign countries. About Kura Oncology
Location: 12730 High Bluff Drive, Suite 400, California, 92130, US | Website: www.kuraoncology.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
881.6M
Cash
491.5M
Avg Qtr Burn
-38.68M
Short % of Float
20.76%
Insider Ownership
1.07%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tipifarnib Details Cancer, Head and neck cancer, Head and neck squamous cell carcinoma | Phase 2 Data readout | |
Ziftomenib Details Acute myeloid leukemia, Blood cancer, Cancer | Phase 2 Data readout | |
Tipifarnib Details Cancer, Lymphoma, T-cell lymphoma | Phase 2 Update | |
Tipifarnib + alpelisib Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Update | |
KO-2806 (FTI inhibitor) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Data readout | |
KO-2806 (FTI inhibitor) + cabozantinib Details Solid tumor/s, Renal cell carcinoma, Cancer | Phase 1 Data readout | |
Ziftomenib + gilteritinib Details Acute myeloid leukemia, Blood cancer, Cancer | Phase 1 Data readout | |
Ziftomenib + venetoclax/azacitidine (ven/aza) or cytarabine/daunorubicin Details Acute myeloid leukemia, Blood cancer, Cancer | Phase 1 Data readout | |
Ziftomenib Details Cancer, Gastrointestinal stromal tumors | Phase 1 Initiation |